| Literature DB >> 33393511 |
Belinda S Lennerz1,2,3, Andrew P Koutnik4,5, Svetlana Azova1,2,3, Joseph I Wolfsdorf2,3, David S Ludwig1,2,3.
Abstract
Carbohydrate restriction, used since the 1700s to prolong survival in people with diabetes, fell out of favor after the discovery of insulin. Despite costly pharmacological and technological developments in the last few decades, current therapies do not achieve optimal outcomes, and most people with diabetes remain at high risk for micro- and macrovascular complications. Recently, low-carbohydrate diets have regained popularity, with preliminary evidence of benefit for body weight, postprandial hyperglycemia, hyperinsulinemia, and other cardiometabolic risk factors in type 2 diabetes and, with more limited data, in type 1 diabetes. High-quality, long-term trials are needed to assess safety concerns and determine whether this old dietary approach might help people with diabetes attain clinical targets more effectively, and at a lower cost, than conventional treatment.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33393511 PMCID: PMC7773350 DOI: 10.1172/JCI142246
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808